Roche's Tecentriq wins speedy U.S. review in small cell lung cancer

Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18.